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Abstract
Background: Women testing positive for human papillomavirus (HPV) infection experience increased levels of anxiety that
have been attributed to fears of stigmatization and developing cervical cancer. The objective of this study was to
investigate the association between HPV infection and anxiety in women who were unaware they had been tested
specifically for HPV, to determine if any anxiety experienced by HPV-positive women could be due to causes other than
learning of test results.
Methods: This study was nested within a randomised controlled trial of management of women with abnormal cervical
cytology conducted in the United Kingdom with recruitment between 1999 and 2002. At baseline, prior to having a sample
taken for HPV testing, the results of which were not disclosed, women were assessed for anxiety using the Hospital Anxiety
and Depression Scale and asked about fears of developing cervical cancer (‘‘cancer worries’’); this assessment was repeated
at 12, 18, 24, and 30 months of follow-up. Logistic regression and generalized estimating equations were used for the cross-
sectional (baseline) and longitudinal analyses, respectively.
Results: Among the 2842 participants, there was no association between HPV status and anxiety among white women.
Among non-white women, however, anxiety was less common among HPV-positive than HPV-negative women (adjusted
odds ratio 0.41, 95% confidence interval 0.22 to 0.77). Among non-smokers, cancer worry was more common in HPV-
positive than HPV-negative women; the opposite association was observed among ex-smokers.
Conclusions: Associations between HPV status and anxiety may be explained by factors other than learning of test results
and may vary by ethnicity and lifestyle factors.
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Introduction
Worldwide, an estimated 10% of women are infected with
human papillomavirus (HPV) and with a lifetime risk of infection
near 80%, HPV is considered to be one of the most common
sexually transmitted infections [1,2]. Of over 100 HPV types
known to infect humans, about 15, most commonly types 16 and
18, have been causally linked with cervical cancer, and are
classified as ‘‘high-risk’’ [3,4]. Testing for high-risk HPV is being
considered as an alternative or supplement to current cervical
screening procedures, as it is a more sensitive test than cervical
cytology for the detection of cervical intraepithelial neoplasia and
few cases of cervical cancer are thought to occur in the absence of
HPV infection [5,6,7]. However, there has been concern about
widespread adoption of HPV testing since receipt of positive test
results has been associated with psychological distress [8,9].
Qualitative and quantitative studies have found that women testing
positive for HPV experience anxiety, report feelings of stigmatization,
and worry about disclosing test results to their partner, family, and
friends [8,9,10]. Studies in women with low-grade abnormal cytology
results, who may already have elevated anxiety from learning of these
results, have reported similar findings. In these studies, anxiety,
distress, and intrusive thoughts were also more common in HPV-
positive women than those testing negative [8,11]. In studies
comparing women with normal and abnormal cytology, however,
agreaterdifferenceinanxietyandpsychologicaldistresswasobserved
between HPV-positive and HPV-negative women in the group with
normal cytology than in those with abnormal results [9,12].
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have been conducted after women had received their test results
and have focused on the positive test result as the only potential
cause of anxiety [8,9,11]. In these studies, it has not been possible
to separate the effects of learning of a positive test result from the
effects of any baseline differences in anxiety between HPV-positive
and HPV-negative women. Lifestyle and sociodemographic risk
factors for HPV include age, ethnicity, socioeconomic status, and
smoking status; these are characteristics also associated with
anxiety [13,14,15,16]. As such, it is possible that elevated anxiety
following HPV testing is at least partially attributable to HPV-
positive women having more risk factors for anxiety than those
who are HPV-negative. Results consistent with this hypothesis
have been suggested by the ARTISTIC trial, in which anxiety and
psychological distress were observed to be more common in HPV-
positive women than HPV-negative women even though women
were unaware of their HPV test results, which had not been
disclosed to them [12].
The aim of this study was to determine if adverse psychological
effects experienced by HPV-positive women could be due to
causes other than learning of test results. We examined whether
anxiety and cancer worries were more common in HPV-positive
than in HPV-negative women using data from a large, population-
based sample of women undergoing management for low-grade
abnormal cervical cytology, who had undergone HPV testing but
were not aware of their test result. We also assessed whether the
association between HPV status and anxiety differed by lifestyle or
sociodemographic risk factors for HPV and anxiety.
Methods
Ethics statement
Ethics approval was obtained from the joint research ethics
committee of NHS Grampian and the University of Aberdeen, the
Tayside committee on medical research ethics, and the Notting-
ham research ethics committee. All participating women provided
written informed consent.
Participants
The study population consisted of women who participated in
TOMBOLA (Trial Of Management of Borderline and Other
Low-grade Abnormal smears), a randomised controlled trial to
determine the most effective and efficient management for women
with low-grade abnormal cervical cytology (borderline nuclear
abnormalities or mild dyskaryosis, broadly equivalent to ASCUS
[atypical squamous cells of undetermined significance] and LSIL
[low grade squamous intraepithelial lesion] in the Bethesda system)
[17,18,19,20,21,22,23]. Between 1999 and 2002, women in the
Grampian and Tayside (Scotland) and Nottingham (England)
areas aged 20–59 years undergoing routine cervical screening in
primary care and who had had a recent routine cytology result
classified as low-grade abnormal were invited to participate in the
trial. Women who were pregnant or who had previously been
treated for cervical lesions were excluded. After entry into the trial,
women were randomised to receive either initial colposcopy or
cytological surveillance (cytology repeated at 6-monthly intervals
in primary care), and were followed for a three-year period.
Outcome assessment: anxiety and cancer worry
Anxiety was the primary outcome of interest assessed by means
of the anxiety subscale of the Hospital Anxiety and Depression
Scale (HADS) [24]. Although the HADS was originally intended
for use in hospital outpatients, it has since been shown to be valid
for screening for anxiety and depression in primary care and
community settings [25]. The instrument was administered during
the TOMBOLA recruitment appointment at a hospital clinic, a
median of approximately 10 weeks following the initial low-grade
abnormal cytology result, and again at 12, 18, 24, and 30 months
of follow-up by mailed questionnaire. Women were asked to
respond to each question in relation to how they had been feeling
over the previous week.
Cervical cancer worry was a secondary outcome of interest.
Such worries are commonly reported in women undergoing
follow-up for abnormal cervical cytology results [26]. Since 60% of
women without anxiety in our series reported cervical cancer
worry (Table 1), we therefore considered that cancer worry might
be a more specific measure of psychological distress for this
population of women. Cervical cancer worry was measured in the
recruitment questionnaire by the question ‘‘Since getting my
smear result I have been worried that I may have cervical cancer’’,
with choices of responses in the form of a Likert scale (strongly
agree, moderately agree, slightly agree, slightly disagree, moder-
ately disagree, strongly disagree) [26]. Mailed questionnaires were
used to measure cancer worry after 12, 18, 24, and 30 months of
follow-up.
Exposure assessment: HPV testing
Details of the HPV testing have been described elsewhere [17].
Briefly, cervical samples were obtained from participants at the
TOMBOLA recruitment appointment following administration of
the sociodemographic (see below) and psychosocial questionnaires.
Women were told that the cervical swab would be used for
additional testing, the results of which they would not receive.
They were not told that the swabs would be used for testing HPV
infection. DNA was extracted from the swabs using a QIAampH
DNA Mini Kit (Qiagen UK) and amplified using real-time
polymerase chain reaction. Women were classified as HPV-
positive at baseline if they were infected with any of fourteen high-
risk HPV types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
66, or 68). The results of the HPV test were not disclosed to the
participants or to health professionals involved in their care.
Covariate assessment
Information on sociodemographic characteristics was collected
at study entry during the TOMBOLA recruitment appointment
and consisted of questions concerning the participants’ ethnicity,
reproductive history, education, smoking, and physical activity.
Statistical analysis
The study population was restricted to the 3258 women who
completed at least half of the HADS anxiety subscale at baseline
(recruitment) (i.e., they had completed 4 or more of the 7
questions). Best subset regression was used to impute scores for
women who had answered at least half, but not all, of the anxiety
subscale questions at any time point (n=27, 24, 25, 18, 10 at
baseline and 12, 18, 24, and 30 months of follow-up, respectively).
Women (n=416) with baseline values missing for cancer worry
(n=36), HPV status (n=351), or any covariates included in the
multivariable analysis (n=29) were excluded, leaving 2842 in the
final analysis. Outcomes were dichotomized, with significant
anxiety defined as a score of 8 or greater on the HADS anxiety
subscale (HADS anxiety subscale range: 0–21) [24,27] and cervical
cancer worry defined as any positive response to the question on
cervical cancer worry (strongly, moderately, or slightly agree).
HPV status was categorised as high-risk positive or negative.
Cross-sectional analyses were performed using logistic regres-
sion to estimate odds ratios (OR) and 95% confidence intervals
(CI) for associations at baseline between HPV status (exposure)
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equations with an autoregressive correlation structure were used to
take into account the longitudinal nature of the data when
outcome measurements from baseline and 12, 18, 24, and 30
months of follow-up were included. To explore the impact of using
a defined cut-off for the definition of significant anxiety, a
sensitivity analysis was undertaken. The analyses were repeated
treating HADS anxiety score as a continuous variable using linear
regression and generalized estimating equations for the cross-
sectional and longitudinal analyses, respectively. The analyses
were also repeated without imputation for missing HADS anxiety
scores. In each analysis, all variables aside from the outcomes
(anxiety and cancer worry) were assumed to be time-invariant.
Potential confounders or effect measure modifiers considered in
the models included: trial centre (A, B, C), trial arm (colposcopy,
cytological surveillance), age at recruitment smear (20–29, 30–39,
40–49, 50–59), ethnicity (white, non-white), smoking (never, ex-,
or current smoker), and neighbourhood deprivation (quintiles of
the Carstairs Index [28]). To assess effect measure modification,
cross-product terms were fitted between exposure (HPV status)
and each covariate, with terms retained in the final model if the
likelihood ratio test (cross-sectional analysis) or score test
(longitudinal analysis) was statistically significant (i.e., p,0.05).
All analyses were performed in SAS version 9.2 (SAS Institute,
Cary, NC).
Results
Participant characteristics
At study entry, 1164 (41%) women were HPV-positive (Table 1).
Over half of participants (58%) were classified at baseline as
having significant anxiety and slightly more than two-thirds (68%)
reported cervical cancer worry. In univariate analysis, trial centre,
age, and smoking status were associated with each of HPV
infection, anxiety, and cancer worry.
HPV status and anxiety
In the cross-sectional analysis, no association was found between
HPV status alone and anxiety (crude OR 1.04, 95% CI 0.90–
1.21). In the fully-adjusted model, an interaction term between
HPV status and ethnicity remained (p=0.03). Anxiety was equally
likely in HPV-positive and HPV-negative white women (adjusted
OR 1.02, 95% CI 0.86–1.20), but was less likely in HPV-positive
than HPV-negative non-white women (adjusted OR 0.42, 95% CI
Table 1. Characteristics of the 2842 participants with respect to HPV status, cancer worry, and anxiety at baseline.
HPV status Cervical cancer worry Anxiety
N (column %) N (column %) N (column %)
Variable Level Positive Negative p* Yes No p* Yes No p*
N (row %) 1164 (41.0) 1678 (59.0) 1938 (68.2) 904 (31.8) 1645 (57.9) 1197 (42.1)
Cancer worry Yes 352 (30.2) 552 (32.9) 0.13 978 (81.7) 960 (58.4) ,0.01
No 812 (69.8) 1126 (67.1) 219 (18.3) 685 (41.6)
HADS anxiety score 0–7 667 (57.3) 978 (58.3) 0.60 960 (49.5) 685 (75.8) ,0.01
$8 497 (42.7) 700 (41.7) 978 (50.5) 219 (24.2)
Trial arm Colposcopy 575 (49.4) 855 (51.0) 0.41 991 (51.1) 439 (48.6) 0.20 613 (51.2) 817 (49.7) 0.42
Cytological
surveillance
589 (50.6) 823 (49.0) 947 (49.9) 465 (51.4) 584 (48.8) 828 (50.3)
Trial centre A 363 (31.2) 508 (30.3) 0.03 531 (27.4) 340 (37.6) ,0.01 331 (27.7) 540 (32.8) 0.01
B 227 (19.5) 396 (23.6) 416 (21.5) 207 (22.9) 272 (22.7) 351 (21.3)
C 574 (49.3) 774 (46.1) 991 (51.1) 357 (39.5) 594 (49.6) 754 (45.8)
Age 20–29 705 (60.6) 513 (30.6) ,0.01 793 (40.9) 425 (47.0) ,0.01 515 (43.0) 703 (42.7) 0.03
30–39 276 (23.7) 478 (28.5) 557 (28.7) 197 (21.8) 342 (28.6) 412 (24.1)
40–49 138 (11.9) 468 (27.9) 421 (21.7) 185 (20.5) 247 (20.6) 359 (21.8)
50–59 45 (3.9) 219 (13.1) 167 (8.6) 97 (10.7) 93 (7.8) 171 (10.4)
Ethnicity White 1114 (95.7) 1606 (95.7) 1.00 1846 (95.3) 874 (96.7) 0.08 1141 (95.3) 1579 (96.0) 0.39
Non-white 50 (4.3) 72 (4.3) 92 (4.8) 30 (3.3) 56 (4.7) 66 (4.0)
Smoking status Non-smoker 527 (45.3) 827 (49.3) ,0.01 897 (46.3) 457 (50.6) 0.05 510 (42.6) 844 (51.3) ,0.01
Ex-smoker 154 (13.2) 339 (20.2) 706 (36.4) 289 (32.0) 485 (40.5) 510 (31.0)
Current smoker 483 (41.5) 512 (30.5) 335 (17.3) 158 (17.5) 202 (16.9) 291 (17.7)
Carstairs deprivation
index
Highest quintile
(least deprived)
153 (13.1) 258 (15.4) ,0.01 283 (14.6) 128 (14.2) 0.09 157 (13.1) 245 (15.4) ,0.01
2
nd quintile 192 (16.5) 346 (20.6) 353 (18.2) 185 (20.5) 200 (16.7) 338 (20.6)
3
rd quintile 167 (14.4) 294 (17.5) 304 (15.7) 157 (17.4) 196 (16.4) 265 (16.1)
4
th quintile 314 (27.0) 414 (24.7) 490 (25.3) 238 (26.3) 319 (26.7) 409 (24.9)
Lowest quintile
(most deprived)
338 (29.0) 366 (21.8) 508 (26.2) 196 (21.7) 325 (27.2) 379 (23.0)
*p-value from chi-square test.
doi:10.1371/journal.pone.0021046.t001
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(Table 2). When analyses were repeated without imputation of
missing data, the results did not change (data not shown).
Results from the sensitivity analyses with HADS anxiety score
considered as a continuous variable were similar. No association
was observed between HPV status and HADS anxiety score (cross-
sectional: b=0.23, 95% CI 20.11 to 0.56, longitudinal: b=0.19,
95% CI 20.10 to 0.49). Unlike the analysis with dichotomized
HADS score, no interaction term remained in the final adjusted
model. Although the interaction term between HPV status and
ethnicity did not reach formal statistical significance (p=0.13),
there was a weak positive association between HPV status and
HADS anxiety score in white women while in non-white women,
HPV infection appeared to be associated with lower anxiety scores
(cross-sectional: b=20.52, 95% CI 22.13 to 1.08, longitudinal:
b=21.05, 95% CI 22.42 to 0.31).
HPV status and cancer worry
Both the cross-sectional and longitudinal analyses suggested
weak associations between HPV status and cancer worry, with
cancer worry more likely among HPV-positive women than HPV-
negative women (cross-sectional: crude OR 1.13, 95% CI 0.96–
1.33, longitudinal: crude OR 1.25, 95% CI 1.12–1.39). In the fully
adjusted analysis, all interaction terms were removed from the
model except that between HPV and smoking status (cross-
sectional: p,0.01, longitudinal: p=0.02). Both the cross-sectional
and longitudinal analyses suggested that among non-smokers
cancer worry was more common in HPV-positive women than
HPV-negative women (Table 2). The association was not apparent
in current smokers, while in ex-smokers the opposite association
was seen, with cancer worry more common in HPV-negative than
HPV-positive women.
Discussion
Differences in the association between anxiety and HPV status
were observed by ethnicity, with anxiety less common in HPV-
positive compared to HPV-negative non-white women, while
cancer worry was more common among HPV-positive women,
but only among non-smokers. In the total population no association
between HPV status and anxiety was observed, in contrast to
previously reported findings from the ARTISTIC trial [12].
A major strength of this study was that participants were
assessed for anxiety prior to their HPV test and were not told
specifically that they were receiving such a test, and were not told
their results. As a result, receipt of positive test results can be
excluded as an explanation for anxiety or cancer worry
experienced by HPV-positive women. It is possible that a few
women knew their HPV status from previous tests, but it seems
unlikely that this would substantially affect results given the low
awareness of HPV and its relation to cervical cancer at the time
this study was conducted [29]. The results suggest that something
other than knowledge of the HPV results is influencing
psychological wellbeing.
Reasons for the observed differences in the associations by
ethnicity and smoking status are not immediately obvious, but
there are several possible explanations. Pre-existing or long-term
anxiety share risk factors with HPV infection, and it is possible that
these associations may differ between strata of these risk factors or
exist only in certain segments of the population. Information on
risk factors related to sexual behaviours which might also correlate
with anxiety, such as number of sexual partners and age at first
intercourse, were not available in this study to further investigate
this hypothesis [13]. Second, the prevalence, presentation, and
response to treatment of anxiety are recognized to differ
substantially by ethnicity, and these differences are hypothesized
to have both cultural and biologic explanations [14,15,30]. These
cultural and biologic determinants of anxiety may explain the
observed differences between HPV and anxiety. A third possibility
is that there are biologic mechanisms responsible for the
association between HPV infection and anxiety, and these
mechanisms differ by ethnicity or behaviour. An increasing body
of evidence suggests that viral infections may be able to affect
mood and behaviour [31,32,33]. It has been noted that some
cancer patients treated with interferon therapy experience
symptoms of anxiety and depression, suggesting that when the
immune system produces these same signalling molecules during
immune response to infection, similar behavioural symptoms may
be possible [33]. It is unclear whether this sort of mechanism could
provide an explanation for the association between HPV and
psychological distress varying by ethnicity or smoking, but further
investigation is warranted on the basis of these findings. A fourth,
and perhaps likely, explanation for these results is that of chance.
There were no specific a priori hypotheses regarding effect measure
modification by smoking or ethnicity; in particular, with a small
number of non-white women in the study (n=122), investigation
of this association in populations with larger proportions of non-
white women would be beneficial.
Table 2. Associations between HPV status and anxiety by ethnicity, and HPV status and cancer worry by smoking status.
Outcome Estimate Cross-sectional OR (95% CI)* p for interaction{ Longitudinal OR (95% CI) { p for interaction{
Anxiety Overall estimate 0.98 (0.83–1.15) 0.03 0.99 (0.86–1.14) ,0.01
White women 1.02 (0.86–1.20) 1.03 (0.90–1.18)
Non-white women 0.42 (0.20–0.90) 0.41 (0.22–0.77)
Cancer worry Overall estimate 1.16 (0.98–1.38) ,0.01 1.17 (1.05–1.31) 0.02
Non-smokers 1.55 (1.21–1.98) 1.36 (1.16–1.59)
Current smokers 0.84 (0.63–1.11) 0.97 (0.80–1.16)
Ex-smokers 0.46 (0.25–0.84) 0.69 (0.46–1.02)
*Odds ratio (OR) and 95% confidence interval (CI) for anxiety in HPV-positive (compared to HPV-negative) women at baseline, adjusted for trial centre, trial arm, age,
smoking status, and Carstairs Index.
{p-value is for cross-product term in the regression model.
{Odds ratio and 95% confidence interval for anxiety at baseline and over course of follow-up (12, 18, 24, 30 months) in HPV-positive (compared to HPV-negative)
women where HPV status was determined at baseline, adjusted for trial centre, trial arm, age, ethnicity, and Carstairs Index.
doi:10.1371/journal.pone.0021046.t002
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availability of HPV status at a single point in time is a limitation of
this study. It would be unlikely that most women who were HPV-
positive at baseline would remain so for the length of the three-
year follow-up. HPV testing was also conducted at the end of the
follow-up period, approximately 3 years post-recruitment. In the
subgroup of 1639 women participating in TOMBOLA who had
HPV status determined both at enrolment and at exit, 215 (13%)
were HPV-positive at both time points. We have not conducted
further analysis on this point, because not all of this subgroup had
been eligible to participate in the psychosocial assessment. It is
conceivable that if biologic effects of infection on anxiety exist,
they would be most likely to be observed in women with persistent,
rather than transient, HPV infection. A further limitation of the
study is potential inability to detect weak effects on anxiety, since
anxiety may have been initially elevated among participants due to
the previous abnormal cytology result that was a condition of study
eligibility [35]. Results from the ARTISTIC trial have suggested
that while psychosocial distress and anxiety are elevated in HPV-
positive compared to HPV-negative women with negative
cytology, there is less of a difference observed in women with
low-grade abnormal cytology [12]. The raised anxiety in women
with low-grade abnormal cytology results decreases following
further investigation and intervention [36]. This would suggest
that the longitudinal analysis may be better suited to detecting
longer-term anxiety not attributable to initial cytology results; in
fact, the results from cross-sectional and longitudinal analyses were
similar.
In the total study population, anxiety and cervical cancer worry
were no more common in HPV-positive than HPV-negative
women with low-grade abnormal cervical cytology who were
unaware of their HPV status. Secondary analyses from this study
suggest differences in associations between HPV status and anxiety
and cervical cancer worry by ethnicity and smoking status.
Explanations for these observed associations remain unclear and
may be due to chance; however, it is possible that factors other
than knowledge of test results, such as ethnicity and smoking
status, may be important in explaining occurrence of anxiety and
other adverse psychosocial outcomes in this population.
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